This study compared the immunomodulating properties of viable and killed Yersinia enterocolitica O9 in BALB/c mice. At 10 days after infection by the intragastric route, ex vivo assays showed a suppression of spleen cell proliferation in response to Salmonella lipopolysaccharide, concanavalin A and heat-killed yersiniae. Mice infected with Y. enterocolitica O9 for 10 days resisted the challenge with a lethal dose of Listeria monocytogenes. In contrast, intravenous administration of heat-killed yersiniae did not modify the ability of spleen cells to proliferate in response to lipopolysaccharide or concanavalin A, and proliferation in response to killed yersiniae was significantly increased. By 3 days after administration of a single dose of heat-killed yersiniae, the resistance of mice to L. monocytogenes challenge was significantly increased. Our findings show profound differences in immunomodulation by viable and heat-killed yersiniae, but suggest that killed yersiniae retain interesting immunomodulating properties.
Introduction
Yersinia enterocolitica is a human enteropathogen that may cause enteritis, terminal ileitis and mesenteric adenitis. Additionally, extraintestinal and systemic infections may be caused by the so-called high-virulence serotypes in normal hosts, or by low-virulence serotypes in immunocompromised hosts and in iron-overloaded patients. Human yersiniosis may be followed by non-septic, immunopathologic sequelae such as reactive arthritis, erythema nodosum, and autoimmune thyroiditis. Several comprehensive reviews focusing on the pathogenesis and clinical signi¢cance of Y. enterocolitica have been recently published [1^3] . The pathogenic capacity of Y. enterocolitica depends on an array of virulence factors, some of which are encoded by chromosomal genes [4] , whereas others, including an antiphagocytic type III secretion system, are encoded by a 70-kb virulence plasmid (pYV) [5, 6] .
We have previously demonstrated that low-virulence Y. enterocolitica strains possess immunomodulatory properties [7^9] . Interestingly, experimental infection with IP383, a pYV-bearing strain belonging to the low-virulence serotype O9, confers on BALB/c mice signi¢cant resistance levels against transplantation of the syngeneic lymphoma LSTRA or challenge with a lethal dose of the intracellular pathogen Listeria monocytogenes [8, 9] . Using a murine intestinal infection model that mimics the human infection with low-virulence serotypes [10] , we have shown the presence of profound immunological alterations in animals with few or no symptoms of disease [9] . However, the bacterial fractions responsible for the immunomodulating e¡ects are unknown. Observations regarding immunomodulation by low-virulence serotypes have been always performed with experimentally infected mice [7^9], and it is not known whether killed yersiniae retain the capacity to cause non-speci¢c modi¢cations on the immunity mechanisms. In the present work, we compared the ability of live and heat-killed organisms from strain IP383 to modify the proliferation of mouse lymphocytes in response to B-cell and T-cell mitogens.
Materials and methods

Mice
Six-to eight-week-old female BALB/c mice were provided by the Unit of Animal Experimentation of the University of Granada (Granada, Spain). They were maintained under pathogen-free conditions.
Experimental infection with Y. enterocolitica
Strain IP383 of Y. enterocolitica was used in all experiments. It is a serotype O9 strain that carries the virulence plasmid pYV [11] . Bacteria were grown on tryptic soy agar (Difco Laboratories) at 25 ‡C for 24 h, harvested, washed and resuspended in sterile water to obtain 10 9 bacteria ml 31 . Mice were infected by the intragastric route with 100 Wl of bacterial suspension.
Treatment with killed yersiniae
A preparation of heat-killed yersiniae (HKY) was obtained by heating IP383 organisms at 90 ‡C for 15 min, and 100 Wl of this suspension was given by the intravenous route. The doses and days of treatment are indicated in each experiment.
Spleen cell proliferation assay
Spleens were removed aseptically and homogenized in sterile Hanks' balanced salt solution (Sigma Chemicals, St. Louis, MO, USA). Splenocytes were sedimented by centrifugation, resuspended in red blood cell lysing bu¡er (Sigma) for 10 min, washed, and resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 50 WM 2-mercaptoethanol, penicillin G (100 U ml 31 ), streptomycin (100 Wg ml 31 ), amphotericin B (0.25 Wg ml 31 ), 1 mM sodium pyruvate, and 2 mM L-glutamine (Sigma). Cell suspensions were distributed (5U10 5 viable cells per well) into 96-well tissue culture clusters with £at-bottom wells (Costar, Cambridge, MA, USA). Salmonella typhi lipopolysaccharide (LPS ; Sigma) was used at 2.5 Wg ml 31 as B-cell mitogen, and concanavalin A (ConA; Sigma) was used at 1 Wg ml 31 as T-cell mitogen. HKY were used in proliferation assays at 10 7 organisms ml 31 . These mitogen concentrations have been shown to induce optimum splenocyte proliferation in our assay conditions [9] . After incubation at 37 ‡C in 5% CO 2 for 3 days, proliferation of spleen cells was measured by colorimetric reading of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction as described by Mosmann [12] .
Challenge with L. monocytogenes
A virulent isolate of L. monocytogenes was kindly provided by Dr. De La Rosa (Hospital Virgen de las Nieves, Granada, Spain). Bacteria were grown on blood agar at 37 ‡C for 24 h, harvested in sterile phosphate-bu¡ered saline, washed twice and 10 3 organisms were injected in a mouse tail vein. Mice were observed daily and deaths were recorded.
Statistical analysis
The di¡erences in splenocyte number and in splenocyte proliferative responses between control and treated groups were analyzed using Student's t-test. The di¡erences in survival of L. monocytogenes-infected mice were analyzed by the Wilcoxon rank test for non-parametric unpaired analysis. A P value of less than 0.05 was considered signi¢cant.
Results
E¡ect of HKY on spleen cell number and proliferation in response to mitogens
Infection with IP383 is able to induce macrophage activation linked to an inhibition of the capacity of splenocytes to proliferate in response to both B-cell and T-cell mitogens [9] . To assess if live Y. enterocolitica were necessary for the observed suppression of ex vivo lymphoproliferation, the responses of spleen cells from 10-day-in- Table 1 Total count and ex vivo proliferation in response to mitogens of spleen cells from mice treated with repeated intravenous injections of HKY in comparison to spleen cells from mice infected with Y. enterocolitica fected mice, HKY-treated mice and untreated controls were compared. Based on previous work [13] , it was assumed that a low number of viable yersiniae move from the intestinal mucosa to the blood and spleen. In an attempt to imitate the interactions that probably occur in infected animals between biologically active fractions of yersiniae and immunity cells, HKY were given on days 0, 3, 5 and 7 (mice were killed on day 10). Doses of 10 5 , 10 6 and 10 7 HKY per mouse were assayed. As shown in Table 1 , the proliferative responses of spleen cells from 10-day-infected mice to LPS, ConA and HKY were signi¢cantly decreased with regard to those of untreated controls. Suppressive e¡ects were not observed when mice were treated with HKY. On the contrary, the response to HKY was increased by treatments with 10 6 and 10 7 killed bacteria. Data in Table 1 also show that 10-dayinfected mice developed a marked splenomegaly; a similar e¡ect was only obtained with the highest dose of HKY.
In the following set of experiments, the e¡ects of a single dose of 10 7 HKY given on day 0 or day 7 were examined. Both treatments resulted in signi¢cant increases of lymphoproliferation in response to HKY, without induction of splenomegaly (Table 2) .
Yersinia-induced resistance against challenge with
L. monocytogenes
As shown in Fig. 1 , mice that were infected with Y. enterocolitica on day 0 survived challenge by the intravenous route on day 10 with a dose of L. monocytogenes that was lethal for 100% of control mice. Mice that received a single dose of 10 7 HKY on day 7 showed a partial but signi¢cant protection.
Discussion
The present work shows that, despite the profound differences of immunomodulating activity between live and killed Y. enterocolitica organisms, HKY retain an interesting ability to modify the immunity mechanisms.
It is generally accepted that bacterial elimination in L. monocytogenes infection is mediated by stimulation of macrophages with interferon-Q (IFN-Q), resulting in the macrophage production of listericidal reactive nitrogen intermediates [14] , that may be responsible for the inhibition of lymphoproliferative responses ex vivo [15] . Our previous studies support this hypothesis to explain the decreased spleen cell response to mitogens and the protection against L. monocytogenes challenge in Y. enterocolitica-infected mice [9] . A similar picture has been described in mice infected with an attenuated strain of Salmonella typhimurium which also induces a transient protection against L. monocytogenes and a suppression of splenocyte proliferation in response to mitogens [16] .
The interactions between HKY and the immunity mechanisms seem to be quite di¡erent. Spleen cell proliferation in response to LPS and ConA was una¡ected, whereas the response to HKY was potentiated. This potentiation cannot be attributed to a speci¢c immune response elicited by killed yersinia injections, since it was observed as soon as 3 days after a single dose of HKY.
Di¡erences in cytokine induction by viable and killed Table 2 Total bacteria have been reported by several authors. Live Salmonella spp., Helicobacter pylori, L. monocytogenes or Mycobacterium bovis induced a type 1 T-helper cell cytokine response that is not elicited by their killed counterparts [17^20]. However, killed bacteria may retain the ability to stimulate spleen cells non-speci¢cally to produce some amount of IFN-Q [19] . In fact, a number of microbial products are able to activate cell and cytokine networks resulting in the production of IFN-Q [21^23]. Our data showing that administration of HKY resulted in a limited but signi¢cant increase of resistance against L. monocytogenes infection suggest that Y. enterocolitica O9 possess bacterial modulins with potentially interesting pharmacological properties. The nature of these modulins is still to be identi¢ed. Serotype O8 yersiniae, which ¢t in the highvirulence serotypes, possess a lipoprotein with mitogenic activity for murine B-cells [24] and a superantigen that stimulates murine and human T-cells in a MHC class-IIdependent and VL-speci¢c manner [25] , but similar fractions still have not been demonstrated in low-virulence serotypes. LPS and other components of the outer membrane of Gram-negative bacteria have capacity for immunomodulation [26] . LPS of Y. enterocolitica is able to enhance the antibody response to a protein antigen [27] . Also, pYV-encoded proteins should be involved in immunomodulation. For instance, treatment of mice with the so-called virulence antigen, denoted LcrV, results in modulation of the production of IFN-Q and interleukin-10 by spleen cell cultures [28] . We have found that the presence of pYV in£uences the pattern of immunomodulation, although this in£uence may be explained by the critical role of the virulence plasmid in the in vivo spreading of yersiniae [8] . Experiments to de¢ne the nature of modulins of Y. enterocolitica O9 are in progress.
